Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

被引：1
|
作者：
Muggia, F.
Safra, T.
Borgato, L.
Gandhi, A.
Mancinc, G.
Gabizon, A.
Liebes, L.
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] IOV, Padua, Italy
[4] SZMC, Jerusalem, Israel
[5] NYU, Inst Canc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evaluating the effects of bortezomib (Velcade®) on the pharmacokinetics (PK) of pegylated liposomal doxorubicin (Doxil®, PLD)
    La-Beck, Ninh M.
    Walko, Christine M.
    Scoggins, Lakia
    Dees, E. Claire
    Orlowski, Robert Z.
    Wu, Huali
    Amantea, Michael
    Fardin, Mahsa
    Zamboni, William
    CANCER RESEARCH, 2012, 72
  • [22] Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
    Monk, Bradley J.
    Herzog, Thomas J.
    Kaye, Stanley B.
    Krasner, Carolyn N.
    Vermorken, Jan B.
    Muggia, Franco M.
    Pujade-Lauraine, Eric
    Park, Youn C.
    Parekh, Trilok V.
    Poveda, Andres M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (15) : 2361 - 2368
  • [23] Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer
    Kikuchi, Y., Sr.
    Kouta, H.
    Kikuchi, R.
    Takano, M.
    Kita, T.
    Kudoh, K.
    Aoki, D.
    Sugiyama, T.
    Isonishi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
    Oaknin, Ana
    Barretina, Pilar
    Perez, Xavier
    Jimenez, Laura
    Velasco, Montserrat
    Alsina, Maria
    Brunet, Joan
    Ramon Germa, Josep
    Beltran, Miguel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 87 - 91
  • [25] Implications of BRCA mutations on recurrent ovarian cancer outcome treated with pegylated liposomal doxorubicin (PLD)
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Donach, Martin Edward
    Rolnitzky, Linda
    Geva, Ravit
    Peles, Sharon
    Pua, Thara
    Novetsky, Akiva
    Gabizon, Alberto
    Muggia, Franco
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [26] Combination of pegylated-liposomal doxorubicin (PLD) and bevacizumab (B) (PLD-B) in sarcoma (SAR)
    Skubitz, K. M.
    Haddad, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
    Stebbing, J
    Gaya, A
    CANCER TREATMENT REVIEWS, 2002, 28 (02) : 121 - 125
  • [28] Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    Newhouse, Rebecca
    Nelissen, Ellen
    El-Shakankery, Karim Hussien
    Rogozinsk, Ewelina
    Bain, Esme
    Veiga, Susana
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (07):
  • [29] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [30] Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    Lawrie, Theresa A.
    Bryant, Andrew
    Cameron, Alison
    Gray, Emma
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07):
12345